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Angiostatin is an inhibitor of angiogenesis, a process which is
necessary for tumour growth and metastasis. It consists of the first
four of five kringle domains of plasminogen (O’Reilly et al, 1994)
and can be generated by the proteolytic cleavage of plasminogen
by metalloelastase (matrix metalloproteinase 12) (Dong et al,
1997). Matrix metalloproteinases 3, 7, and 9 have been reported
also to produce angiostatin-like peptides from plasminogen
(Patterson and Sang, 1997; Lijnen et al, 1998). Furthermore, in the
media of prostate cancer cell lines, angiostatin-generating activity
has been found (Gately et al, 1996). However, this activity was not
attributed to PSA. Rather, plasminogen activators in the obligatory
presence of free sulphydryl donors, were shown to convert plas-
minogen to angiostatin, requiring the activation of plasminogen
(Gately et al, 1997).
Prostate-specific antigen (PSA) is a kallikrein-like serine
proteinase. Under physiological conditions, it is secreted extracor-
porally into seminal fluid, its target substrate being semenogelin.
Three cleavage sites have previously been identified between
amino acid residues Tyr44–Thr45, Leu84–His85, and Tyr136–
Ser137 in the secreted semenogelin I (Lilja et al, 1989). A more
detailed analysis identified a total of 12 cleavage sites in
semenogelin I and seven sites in semenogelin II (Malm et al,
1997).
Only minor amounts of PSA reach the bloodstream from the
prostate and are inhibited by the plasma proteinase inhibitors a-2-
macroglobulin (Leinonen et al, 1996) and a-1-antichymotrypsin
(Lilja et al, 1991). Whereas most tumour-associated proteinases
(like cathepsins B and D, matrix metalloproteinases, plasminogen
activators etc.) are overexpressed enzymes of ubiquitous origin,
the extraordinary specificity of PSA as a tumour proteinase
derives from the fact that no human cell types secrete significant
amounts of PSA other than prostatic glandular cells or prostate
cancer cells.
We now show that PSA converts Lys-plasminogen to bio-
logically active angiostatin-like fragments by cleavage of a single
peptide bond between kringle domains 4 and 5.
MATERIALS AND METHODS
Materials
PSA was purified from seminal plasma according to Zhang et al
(1995). Affinity absorption on Trasylol-Sepharose (Pharmacia)
was added to the procedure according to Christensson et al (1990)
in order to remove possible traces of kallikrein-like proteinases
other than PSA from the preparation. Activity was monitored with
MeO–Suc–Arg–Pro–Tyr–NA (S-2586, Chromogenix). PSA was
electrophoretically pure and > 90% active. Identity and purity of
PSA were confirmed by N-terminal amino acid sequencing.
Electrophoretically pure human Lys-Plasminogen (Plasminogen
HS, Activity >90%. Charge No. 281189) was kindly provided by
Dr Römisch from the research department of Behringwerke
(Marburg, Germany).
Proteolytic cleavage of plasminogen
To determine proteolysis of plasminogen by PSA, 3 mg of PSA
were incubated with 50 mg plasminogen in 10 mM Tris–HCl,
pH 8.0, in a final volume of 10 ml at 37°C. For time course
analysis, samples were started individually at different times so as
to reach their planned end points simultaneously, in order to avoid
artefacts. At end point, all samples were immediately taken up in
reducing sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer, boiled for 2 min and
electrophoresed on 10% polyacrylamide gels (Laemmli, 1970).
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like the test samples. They showed no change after 6 h of incuba-
tion. For control purposes, PSA was inactivated by either 48-h
exposure to 50 mM DFP (Sigma) or by boiling for 30 min. The
inactivated preparations showed no detectable activity on
MeO–Suc–Arg–Pro–Tyr–NA even after prolonged incubation
(24 h).
N-terminal protein sequencing
For N-terminal amino acid sequencing of fragments, 30 mg of PSA
were mixed with 500 mg of plasminogen in a final volume of 90 ml
of 10 mM Tris–HCl, pH 8.0. After incubation at 37°C for 6 h,
90 ml of reducing SDS-sample buffer was added and the sample
was boiled for 2 min. Finally, the material was applied to seven
wells of a 10% PAGE gel, electrophoresed and blotted to a
polyvinyldithioride (PVDF) membrane. After brief staining with
Coomassie blue, the membrane was destained in 50% methanol,
bands were cut out and pooled. The N-termini of the fragments
were determined by automated Edman degradation using the
Protein Sequencer 477A (Applied Biosystems).
Purification of angiostatin-like fragments
Angiostatin-like fragments were purified by lysine sepharose
chromatography (Shi and Wu, 1988). Three milligrams of plas-
minogen were digested with PSA for 20 h to completion as
described above. The sample was then loaded onto a lysine
sepharose column (Pharmacia) equilibrated with 10 mM Tris–HCl
pH 8.0, and the flow-through was collected. Bound proteins were
eluted with 200 mM e-aminocaproic acid. Peak fractions were
dialysed against phosphate-buffered saline (PBS), and the protein
concentrations were determined photometrically. For controls,
angiostatin was generated by elastase digestion of plasminogen
according to O’Reilly et al (1996).
In vitro morphogenesis assay
Human umbilical vein endothelial cells (HUVEC) were purchased
from Cell-Systems (Clonetics). The cells were cultured in
endothelial basal medium (EBM) supplemented with 2% brain
extract (Clonetics). All experiments were performed with cells
from passages 2–6, incubated at least overnight in EBM in absence
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Figure 1 Time course of plasminogen degradation by PSA, 37°C, pH 8.0.
Lane 1: PSA only, 3 mg, at 6 h. Lane 2: plasminogen only, 50 mg, at 6 h.
Lanes 3 to 7: plasminogen with PSA, at 0 h, 1 h, 2 h, 4 h, 6 h. Ten per cent
reducing SDS-PAGE
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Figure 2 Comparison of active versus inactivated PSA. Lane 1: 3 mg of
PSA incubated with 50 mg of plasminogen in 10 mM Tris–HCl, pH 8.0, at
37°C for 6 h. Ten per cent reducing SDS-PAGE. Lane 2: same protocol with
PSA heat-inactivated (100°C for 30 min)
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Figure 3 Plasminogen domain structure showing the N-termini of fragments
a, b, and c. PAP: Preactivation peptide. K1–5: Kringle domains 1–5. The
cleavage sites of metalloproteinases MMP-3, -7 and -9 as well as pancreatic
elastase (E) are indicated
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Figure 4 Purification of angiostatin-like fragments. Plasminogen digested
with PSA to completion (lane 1) was purified by lysine sepharose
chromatography. Fragment c was found in the flow-through (lane 2), while
fragments a and b corresponding to the angiostatin-like fragments bound to
the resin and were eluted in the presence of 200 mM e-aminocaproic acid
(lane 3). Fragments were analysed by 10% non-reducing SDS-PAGEof growth factor-containing brain extract. Matrigel (100 ml)
diluted 1:2.5 with EBM containing 1 nM basic fibroblast growth
factor (bFGF) (R&D) was added to each well of 24-culture plates
at 4°C and then incubated at 37°C for 30 min to induce gelation.
HUVEC (5 ´ 104) were then plated into each well in EBM with
and without different stimulants. The cells were then incubated for
18 h at 37°C. Formation of tubes was evaluated first by phase
contrast microscopy and second by cell counting after treatment of
cells with dispase (Kumar et al, 1998).
RESULTS
Incubation of Lys-plasminogen with PSA generated a set of three
distinct fragments by limited proteolysis at 37°C. SDS-PAGE
analysis of the time course of this reaction is shown in Figure 1.
The three major bands (a, b, and c), with apparent molecular
masses of 44.5 kDa, 41 kDa and 38 kDa, appeared already after
the first hour. With time, the intensity of these bands increased,
while the band corresponding to plasminogen was diminished
simultaneously. After prolonged incubation over 6 h, the frag-
ments a, b, and c persisted without further degradation, whereas
plasminogen was consumed almost completely. No cleavage of
plasminogen was observed when active PSA was substituted by
heat-inactivated PSA (Figure 2) or PSA inactivated with DFP (not
shown).
In order to identify the cleavage sites, fragment bands were
blotted onto PVDF membrane, cut out and analysed for their
N-terminal amino acid sequences. As summarized in Figure 3,
both fragments a and b had the same N-termini (KVYLSEKK)
starting with Lys78. A minor fraction within both fragments
started with Val79, due to a common heterogeneity at this site
(Wallén and Wiman, 1972). Sequencing of fragment c
(ASVVAPPPVV) indicated a cleavage site at Glu439–Ala440,
located between kringles 4 and 5. Sequencing of the bands corre-
sponding to Lys-plasminogen and PSA confirmed their identities.
Angiostatin-like fragments a and b were purified by lysine
sepharose chromatography. Fragment c was found in the flow-
through, while fragments a and b bound to the resin and could be
eluted with e-aminocaproic acid (Figure 4). This finding further
demonstrated that fragments a and b contain the kringle-like
domains. In in vitro morphogenesis assays, fragments a and b
inhibited tubular formation and proliferation of HUVECs with the
same efficacy as elastase-generated angiostatin (Figure 5). Half-
maximal inhibition in this assay was observed at a concentration of
1 mg ml–1. Morphologic assessment by phase-contrast microscopy
showed full inhibition of tubular formation (Figure 6).
DISCUSSION
Both fragments a and b had the same N-terminal amino acid
sequence, which corresponds to the N-terminus of angiostatin and
was identical to that of the starting material, Lys-plasminogen. The
molecular masses of fragments a and b, as determined by SDS-
electrophoresis, were 44.5 kDa and 41 kDa respectively. This is
large enough to cover the kringle domains 1–4 (approximately
370 amino acids), of which angiostatin consists (Figure 3). Since
fragment c resulted from a unique cleavage of peptide bond
Glu439–Ala440, which is located between kringles 4 and 5, it is
most likely that both fragments a and b have identical amino acid
backbones spanning from Lys78 to Glu439, for which a calculated
molecular mass of 41.2 kDa would be expected. The difference in
molecular mass between fragments a and b is attributable to a
variable glycosylation of plasminogen at Asn289: only 50% of
plasminogen molecules are glycosylated at this site with 10–11
monosaccharide units (Hayes and Castellino, 1979).
The molecular mass of fragment c was determined by SDS-elec-
trophoresis as 38 kDa. This corresponds to a calculated molecular
Angiostatin-like fragments generated by PSA 1271
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Figure 5 In vitro morphogenesis assay. Inhibition of endothelial cell
proliferation analysed after tubular formation: affinity-purified fragments a and
b (PSA AST); elastase-generated angiostatin (elastase AST)
A
B
Figure 6 In vitro morhogenesis assay. Inhibition of tubular formation as
analysed by phase contrast microscopy. (A) Medium containing 1 nM bFGF.
(B) Medium containing 1 nM bFGF and 10 mg ml–1 affinity purified fragments a
and bmass of 38.5 kDa for the remainder of the plasminogen molecule,
spanning from Ala440 to the C-terminal Asn791, comprising
kringle 5 and the catalytic domain and resembling mini-
plasminogen (Sottrup-Jensen et al, 1978).
We concluded that both fragments a and b correspond to angio-
statin and are generated from Lys-plasminogen by cleavage of a
single peptide bond between kringles 4 and 5 by PSA. The
affinity-purified fragments a and b had angiostatin-like activity as
shown by the inhibition of tubular formation and proliferation of
HUVECs in the in vitro morphogenesis assays.
Fragment c, the remaining part of plasminogen, was not cleaved
at Arg561, indicating that activation of plasminogen to plasmin
had not taken place. This distinguishes the action of PSA on plas-
minogen from the mechanism described by Gately et al (1996),
who showed that human prostate carcinoma cell lines PC-3,
DU-145 and LNCaP express enzymatic activity that can generate
bioactive angiostatin from plasminogen. They did not attribute this
activity to PSA, however, which is only secreted in significant
amounts from LNCaP (Hasenson et al, 1989). Rather, they
identified urokinase released by PC-3 cells to be sufficient for
angiostatin generation by autocatalysis of plasmin – however, only
in the presence of free sulphydryl donors (Gately et al, 1997).
Thus, it seems that some prostate cancer cells may have two
different means of angiostatin generation: urokinase, which
requires strong reducing agents for artificial disruption of
intramolecular disulphide-bridges and the activation of plasmin,
and PSA, which does not. Considering the specificity of PSA for
the extracorporal catalysis of semenogelin, there being no known
physiological intracorporal substrate for PSA, dystopic release of
PSA in prostate cancer could theoretically lead to paraneoplastic
formation of angiostatin-like activity. Thus, we interpret our
finding not as a physiological but rather an erroneous, patho-
physiological process, which imitates angiostatin generation by
the ubiquitous macrophage proteinases.
Different enzymes are capable of conversion of plasminogen to
angiostatin. Dong et al (1997) showed a role for macrophage
metalloelastase (MME) in the generation of angiostatin in Lewis
lung carcinoma. In vitro, matrix metalloproteinase MMP-9 cleaves
between kringles 4 and 5 at peptide bond Pro446–Pro447
(Patterson and Sang, 1997), and MMP3 (Lijnen et al, 1998) as well
as MMP-7 (Patterson and Sang, 1997) both cleave at the neigh-
bouring peptide bond, Pro447–Val448. This is 7–8 amino acids
downstream from the cleavage site of PSA observed by us.
Pancreatic elastase cleavage sites were mapped to Val449–Val450
and Leu451–Pro452 (Cao et al, 1997). Specificity of the PSA-
cleavage site in our experiments was confirmed by the fact that it
was completely distinct from any other known proteinase cleavage
site in this domain.
Apparently, the scissile peptide chain between kringles 4 and 5
is exposed to the surface of the plasminogen molecule, allowing
for proteolytic attack by proteinases of different specificities and
classes. This resembles the bait region in a-2-macroglobulin
(Sottrup-Jensen et al, 1981). The cleavage site of PSA in this area
is novel and has not been described for any other enzyme. Since
several forms of angiostatin-like plasminogen fragments with
microheterogeneity in this scissile connection peptide region
between kringles 4 and 5 are generated by different proteinases,
angiostatin may be no longer considered a single entity. Rather,
there are multiple isoforms depending on the mechanism of gener-
ation.
We showed for the first time that PSA purified from human
seminal plasma specifically interacts with plasminogen to form
angiostatin-like fragments from plasminogen in a defined, cell-
free system. However, the physiological role of this finding
remains elusive. Is PSA released by prostate cancers likely to get
in contact with large plasma proteins like plasminogen? Alpha-
2-macroglobulin is the major inhibitor of PSA when it reaches the
bloodstream (Leinonen et al, 1996). Some PSA in the plasma of
prostate cancer patients is complexed with a-2-macroglobulin,
requiring that at least some PSA released from prostate cancer
enters the bloodstream in active form. Therefore, PSA may
theoretically react with plasminogen before being inhibited by
plasma proteinase inhibitors. Further, in areas of invasive cancer,
plasma extravasation may take place, with molecules like plas-
minogen (92 kDa) diffusing more readily than the very large
a-2-macroglobulin (800 kDa). Local concentrations of PSA in
tumour tissue may be sufficiently high to cause proteolysis of
plasminogen. Even after prolonged incubation, the fragments from
limited PSA proteolysis were not degraded any further.
In the future, it will be interesting to determine whether genera-
tion of angiostatin by PSA actually does occur in vivo. Since
angiostatin can induce and sustain dormancy of tumours (O’Reilly
et al, 1996), our findings might help to understand the general
clinical observation that prostate cancer has a very low progres-
sion rate.
ACKNOWLEDGEMENTS
We are grateful for the very skilled technical assistance of Margitta
Alt, and for helpful discussion with Professor Rudolf Egbring and
Dr Weingärtner.
REFERENCES
Cao Y, Chen A, An SSA, Ji RW, Davidson D, Cao Y and Llinás M (1997) Kringle
5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem
272: 22924–22928
Christensson A, Laurell C and Lilja H (1990) Enzymatic activity of prostate-specific
antigen and its reactions with extracellular serine proteinase inhibitors. Eur J
Biochem 194: 755–763
Dong Z, Kumar R, Yang X and Fidler IJ (1997) Macrophage-derived metalloelastase
is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell
88: 801–810
Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper
HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC and Soff GA
(1996) Human prostate carcinoma cells express enzymatic activity that
converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer
Res 56: 4887–4890
Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J,
Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N and Soff GA (1997) The
mechanism of cancer-mediated conversion of plasminogen to the angiogenesis
inhibitor angiostatin. Proc Natl Acad Sci USA 94: 10868–10872
Hasenson M, Lundh B, Stege R, Carlstrom K and Pousette A (1989) PAP and PSA
in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone
sensitivity and to cytological grading. Prostate 14: 83–90
Hayes ML and Castellino FJ (1979) Carbohydrate of the human plasminogen
variants J Biol Chem 254: 8772
Kumar R, Yoneda J, Bucana CD and Fidler IJ (1998) Regulation of distinct steps of
angiogenesis by different angiogenic molecules. Int J Oncol 12: 749–757
Laemmli UK: Cleavage of structural proteins during the assembly of the head of
bacteriophage T4 (1970) Nature (Lond.) 227: 680–685
Leinonen J, Zhang WM and Stenman UH (1996) Complex formation between PSA
isoenzymes and protease inhibitors. J Urol 155: 1099–1103
Lilja HR, Abrahamsson P-A and Lundwall A (1989) Semenogelin, the predominant
protein in human semen. J Biol Chem 264: 18894–1900
1272 H-H Heidtmann et al
British Journal of Cancer (1999) 81(8), 1269–1273 © 1999 Cancer Research CampaignLilja HR, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K and
Lövgren T (1991) Prostate specific antigen in human serum occurs
predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 37:
1618–1625
Lijnen HR, Uguwu F, Bini A and Collen D (1998) Generation of an angiostatin-like
fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37:
4699–4702
Malm J, Hellman J and Lilja H (1997) Mapping of the unique enzyme characteristics
of PSA. J Urol 157: 345
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS,
Cao Y, Sage EH and Folkman J (1994) Angiostatin: a novel angiogenesis
inhibitor that mediates the suppression of metastases by a Lewis lung
carcinoma. Cell 79: 315–328
O’Reilly MS, Holmgren L, Chen C and Folkman J (1996) Angiostatin induces and
sustains dormnacy of human primary tumours in mice. Nat Med 2: 689–692
Patterson BC and Sang QA (1997) Angiostatin-converting enzyme activities of
human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9).
J Biol Chem 272: 28823–28825
Shi GY and Wu HL (1988) Isolation and characterization of microplasminogen. A
low molecular weight form of plasminogen. J Biol Chem 263: 17071–17075
Sottrup-Jensen L, Claeys H, Zajdel M, Petersson TE and Magnusson S (1978) The
primary structure of human plasminogen: isolation of two lysine-binding
fragments and one ‘mini’-plasminogen (MW 38 000) by elastase-
catalyzed-specific limited proteolysis. In: Progress in Chemical Fibrinolysis
and Thrombolysis, Vol. 3, Davidson JF, Rowan RM, Samama MM and
Desnoyers PC (eds), pp. 191. Raven Press: New York
Sottrup-Jensen L, Lonblad PB, Stepanik TM, Petersen TE, Magnusson S and
Jornvall H (1981) Primary structure of the ‘bait’ region for proteinases in alpha
2-macroglobulin. Nature of the complex. FEBS Lett 127: 167–173
Wallén P and Wiman B (1972) Characterization of human plasminogen. II.
Separation and partial characterization of different molecular forms of human
plasminogen. Biochem Biophys Acta 257: 122–129
Zhang WM, Leinonen J, Kalkkinen N, Dowell B and Stenman UH (1995)
Purification and characterization of different forms of prostate-specific antigen
in human seminal fluid. Clin Chem 41: 1567–1573
Angiostatin-like fragments generated by PSA 1273
British Journal of Cancer (1999) 81(8), 1269–1273 © 1999 Cancer Research Campaign